XXXX : A Meta-Analysis and Review of the Literature.

@entity1 @entity421 @entity39
Over the past 30 years, treatment advances and the addition of neoadjuvant chemotherapy have led to improved 5-year survival in @entity1 with @entity421 . More recent literature suggests the overall prognosis remains highly variable, with little improvement since the introduction of neoadjuvant chemotherapy. Tumor @entity39 is an important predictor of @entity1 prognosis. Necrosis of more than 90% correlates with overall survival (OS) approaching 75%. We reviewed the history of @entity421 treatment and survival and performed a meta-analysis of the 2000-2011 literature. Forty articles were included in the study. Five-year OS was 63% (95% confidence interval, 60%-66%) in studies that included @entity1 with metastatic and nonmetastatic disease and 71% (95% confidence interval, 67%-76%) in studies that included only @entity1 with nonmetastatic disease. Fifty percent of the @entity1 in the studies of those with nonmetastatic @entity421 achieved 90% @entity39 on histology. Five-year OS and number of @entity1 achieving 90% @entity39 are consistent with previous reports. Research is needed to improve treatment regimens and @entity1 outcomes.
